Sanofi buys into NeuroVive’s cardio drug in Korea

Damian Garde Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug. FierceBiotech ...

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

Eric Palmer The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's ...

Suicide stunner prompts Amgen to dump brodalumab for psoriasis, walk away from AstraZeneca

John Carroll FierceBiotech News

ArGEN-X pairs up with Leo Pharma in a $116M dermatology deal

Damian Garde The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $ 116 ...

Endo sews up $9.2B financing for Par Pharma buyout

Carly Helfand Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $ 8 billion. But to do that, it'll need a loan, and it's agreed to a $ 9.275 billion loan ...

J&J touts a blockbuster-rich pipeline with 10 filings on the horizon

Damian Garde Johnson & Johnson says it's on track to submit more than 10 new drugs for FDA approval over the next four years, and the company believes each of those contenders ...

Hep C landscape shifts again as BMS combo nabs breakthrough tag

Eric Palmer Gilead Sciences and AbbVie caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being ...

Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

Damian Garde The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might ...

ProPublica: Safety questions over GSK’s Advair linger after years on the asthma throne

Carly Helfand U.S. regulators gave GlaxoSmithKline's Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $ 8 billion ...

Genocea’s herpes vaccine hits the mark in Phase II

Damian Garde Genocea Biosciences' in-development vaccine for genital herpes met its goals in a Phase II trial, sending the biotech's shares soaring. FierceBiotech News

Perrigo will talk tie-up if the price is right, CEO says–but Mylan has a ways to go

Carly Helfand Perrigo's not opposed to striking a pact with Mylan–as long as the price is right. The bad news for its suitor, though, is that right now, it's nowhere close. FiercePharma ...

Regeneron speeds toward the FDA with its would-be asthma blockbuster

Damian Garde Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS